|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results suggested that CRT could promote ICAM-1 expression in endothelial cells through PI3K/Akt/eNOS/p38 MAPK signaling mediated TTP accumulation, probably in an inactive form, which may provide a possible proinflammatory mechanism of CRT in RA.
|
30639474 |
2019 |
|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
TTP knockdown potentiated cytokine production in RA FLS and murine fibroblasts, which in the latter case was insensitive to inhibition by ITF2357 treatment.
|
30029685 |
2018 |
|
Rheumatoid Arthritis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
TTP expression was significantly higher in RA than non-inflamed synovium, detected in macrophages, vascular endothelial cells and some fibroblasts and co-localised with MAPK p38 activation.
|
27597652 |
2017 |
|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
MGD |
Endothelial dysfunction in tristetraprolin-deficient mice is not caused by enhanced tumor necrosis factor-α expression.
|
24727475 |
2014 |
|
Rheumatoid Arthritis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
miR-346 controls release of TNF-α protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization.
|
21611196 |
2011 |
|
Rheumatoid Arthritis
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We studied the difference in promoter activity between the two alleles by luciferase assay and found that the promoter activity of TTP promoter region with allele A was around two-fold higher than that with allele G. We conclude that this SNP in the promoter region of the TTP gene mildly affects promoter activity, and thus, may influence the disease activity of inflammatory disorders including RA.
|
18536977 |
2008 |
|
Rheumatoid Arthritis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We measured the gene expression of ARBPs, including tristetraprolin, T-cell intracellular antigen (TIA)-1 and Hu antigen R (HuR), in synovial tissues from RA and osteoarthritis patients. cDNA was constructed from synovial tissues obtained from 21 patients with RA, and those from 12 patients with osteoarthritis.
|
16820934 |
2006 |
|
Rheumatoid Arthritis
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Expression of TNF-alpha, tristetraprolin, T-cell intracellular antigen-1 and Hu antigen R genes in synovium of patients with rheumatoid arthritis.
|
16820934 |
2006 |
|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The data presented here suggest a tentative association between ZFP36 and RA.
|
16546352 |
2006 |
|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
LHGDN |
Gene transduction of tristetraprolin or its active domain reduces TNF-alpha production by Jurkat T cells.
|
16596264 |
2006 |
|
Rheumatoid Arthritis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression.
|
15940758 |
2005 |
|
Rheumatoid Arthritis
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Expression of tristetraprolin (G0S24) mRNA, a regulator of tumor necrosis factor-alpha production, in synovial tissues of patients with rheumatoid arthritis.
|
15170914 |
2004 |
|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
MGD |
Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis.
|
14769925 |
2004 |
|
Rheumatoid Arthritis
|
0.300 |
Biomarker
|
disease |
BEFREE |
The TTP pathway of TNF-alpha and GM-CSF mRNA degradation is a possible novel target for anti-TNF-alpha therapies for rheumatoid arthritis, and also for other conditions proven to respond to anti-TNF-alpha therapy.
|
15535838 |
2004 |
|
Rheumatoid Arthritis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Expression of TTP gene was significantly higher in synovial tissues of RA patients than in OA.
|
15170914 |
2004 |